Analyst consensus rating
Marker Therapeutics Analyst Rating: none
Direct answer
Marker Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.87.
Forecast evidence checked November 10, 2026.
Get free Marker Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.95
- Average price target
- $7.87
- High price target
- $10.00
- Low price target
- $5.60
- Low target gap
- +489.3%
- Target upside
- +727.8%
- High target gap
- +952.3%
- Target range width
- 463%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Marker Therapeutics?
Marker Therapeutics has a verified none consensus. The same dataset has an average price target of $7.87.
How far are Marker Therapeutics's low and high targets from the recorded price?
The low target implies +489.3%, while the high target implies +952.3%.
How many analysts are included in Marker Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Marker Therapeutics's target upside or downside calculated?
The average target of $7.87 is divided by the recorded price of $0.95, then one is subtracted to produce +727.8%. This does not guarantee a future return.
When was Marker Therapeutics's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.